These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36847291)

  • 1. Combined mexiletine and flecainide for severe long QT syndrome type 3.
    Shimizu T; Kawai S; Kawada A; Wakamiya T; Nakano Y; Watanabe S; Iwamoto M
    Pediatr Int; 2023 Jan; 65(1):e15517. PubMed ID: 36847291
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of mexiletine in the management of long QT syndrome.
    Li G; Zhang L
    J Electrocardiol; 2018; 51(6):1061-1065. PubMed ID: 30497731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
    Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
    Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mexiletine in a Newborn with Type 3 Long QT Syndrome: When Access is Difficult.
    Pereira ENS; Sacilotto L; Pessente GD; Guirao C; Carvalho MLP; Pereira ADC; Darrieux FCDC; Scanavacca MI
    Arq Bras Cardiol; 2022 May; 118(5):989-991. PubMed ID: 35613201
    [No Abstract]   [Full Text] [Related]  

  • 5. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
    Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seizure After Minor Head Trauma: A Red Herring?
    Avidan OR; Tayebi K; Del Toro K; Warrier R
    Clin Pediatr (Phila); 2021 Jan; 60(1):64-66. PubMed ID: 32723078
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
    Yang Y; Lv TT; Li SY; Zhang P
    J Cardiovasc Electrophysiol; 2021 Nov; 32(11):3057-3067. PubMed ID: 34427958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome.
    Takahara A; Sugiyama A; Satoh Y; Hashimoto K
    Eur J Pharmacol; 2003 Aug; 476(1-2):115-22. PubMed ID: 12969756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mexiletine on long QT syndrome model.
    Wang HW; Zheng YQ; Yang ZF; Li CZ; Liu YM
    Acta Pharmacol Sin; 2003 Apr; 24(4):316-20. PubMed ID: 12676070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
    Priori SG; Napolitano C; Schwartz PJ; Bloise R; Crotti L; Ronchetti E
    Circulation; 2000 Aug; 102(9):945-7. PubMed ID: 10961955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge.
    Howley LW; DI Maria M; Bailey A; Schaffer MS
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):377-9. PubMed ID: 19793370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
    Benhorin J; Taub R; Goldmit M; Kerem B; Kass RS; Windman I; Medina A
    Circulation; 2000 Apr; 101(14):1698-706. PubMed ID: 10758053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation.
    Blich M; Khoury A; Suleiman M; Lorber A; Gepstein L; Boulous M
    Int Heart J; 2019 Jul; 60(4):979-982. PubMed ID: 31257342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
    Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
    J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.
    Kim HJ; Kim BG; Park JE; Ki CS; Huh J; Youm JB; Kang JS; Cho H
    Sci Rep; 2019 Sep; 9(1):12997. PubMed ID: 31506521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome?
    Tunca Sahin G; Ergul Y
    Ann Noninvasive Electrocardiol; 2018 May; 23(3):e12522. PubMed ID: 29194862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3.
    Kehl HG; Haverkamp W; Rellensmann G; Yelbuz TM; Krasemann T; Vogt J; Schulze-Bahr E
    Circulation; 2004 May; 109(18):e205-6. PubMed ID: 15136511
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
    Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
    Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era.
    Aziz PF; Tanel RE; Zelster IJ; Pass RH; Wieand TS; Vetter VL; Vogel RL; Shah MJ
    Heart Rhythm; 2010 Jun; 7(6):781-5. PubMed ID: 20197117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.